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Summary
Background Previous studies suggested intravenous or nebulised magnesium sulphate (MgSO4) might improve 
respiratory function in patients with acute asthma. We aimed to determine whether intravenous or nebulised MgSO4 
improve symptoms of breathlessness and reduce the need for hospital admission in adults with severe acute asthma.
Methods In our double-blind, placebo-controlled trial, we enrolled adults (aged ≥16 years) with severe acute asthma at 
emergency departments of 34 hospitals in the UK. We excluded patients with life-threatening features or contraindication 
to study drugs. We used a central randomisation system to allocate participants to intravenous MgSO4 (2 g in 20 min) or 
nebulised MgSO4 (three 500 mg doses in 1 h) alongside standard therapy including salbutamol, or placebo control plus 
standard therapy alone. We assessed two primary outcome measures in all eligible participants who started treatment, 
according to assigned treatment group: the proportion of patients admitted to hospital within 7 days and breathlessness 
measured on a 100 mm visual analogue scale (VAS) in the 2 h after initiation of treatment. We adjusted for multiple 
testing using Simes’s method. The trial stopped before recruitment was completed because funding expired. This study 
is registered, number ISRCTN04417063.
Findings Between July 30, 2008, and June 30, 2012, we recruited 1109 (92%) of 1200 patients proposed by the power 
calculation. 261 (79%) of 332 patients allocated nebulised MgSO4 were admitted to hospital before 7 days, as 
were 285 (72%) of 394 patients allocated intravenous MgSO4 and 281 (78%) of 358 controls. Breathlessness was 
assessed in 296 (89%) patients allocated nebulised MgSO4, 357 (91%) patients allocated intravenous MgSO4, and 
323 (90%) controls. Rates of hospital admission did not diﬀ er between patients treated with either form of MgSO4 
compared with controls or between those treated with nebulised MgSO4 and intravenous MgSO4. Change in VAS 
breathlessness did not diﬀ er between active treatments and control, but change in VAS was greater for patients in the 
intravenous MgSO4 group than it was in the nebulised MgSO4 group (5·1 mm, 0·8 to 9·4; p=0·019). Intravenous or 
nebulised MgSO4 did not signiﬁ cantly decrease rates of hospital admission and breathlessness compared with 
placebo: intravenous MgSO4 was associated with an odds ratio of 0·73 (95% CI 0·51 to 1·04; p=0·083) for hospital 
admission and a change in VAS breathlessness of 2·6 mm (–1·6 to 6·8; p=0·231) compared with placebo; nebulised 
MgSO4 was associated with an odds ratio of 0·96 (0·65 to 1·40; p=0·819) for hospital admission and a change in VAS 
breathlessness of –2·6 mm (–7·0 to 1·8; p=0·253) compared with placebo.
Interpretation Our ﬁ ndings suggest nebulised MgSO4 has no role in the management of severe acute asthma in 
adults and at best suggest only a limited role for intravenous MgSO4 in this setting. 
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Introduction
Acute asthma leads to about 60 000 hospital admissions 
per year in England.1 Present guidelines2,3 advise a 
stepwise approach to the management of exacerbations. 
Initially, all patients should receive oxygen, nebulised β2 
agonists, a nebulised anticholinergic drug, and cortico-
steroids. However, bronchodilators act within minutes 
whereas corticosteroids require hours to take eﬀ ect. This 
diﬀ erence suggests a potential role for magnesium 
sulphate (MgSO4) as an additional treatment option in 
the therapeutic gap between nebulised bronchodilators 
and corticosteroids.
MgSO4 has been assessed in intravenous and nebulised 
forms. The nebulised route oﬀ ers the potential advantage 
of a quick onset of action and reduced incidence of 
side-eﬀ ects. Its disadvantages include a reduced dose of 
drug delivered compared with the intravenous form and 
respiratory eﬀ ort on the part of the patient to increase its 
eﬀ ectiveness. The intravenous route provides direct 
access to the venous system, allowing the delivery of high 
drug concentrations. Disadvantages include the need for 
intravenous access and drug administration by infusion 
lasting about 20 min.
Several systematic reviews and meta-analyses have 
assessed the role of intravenous or nebulised MgSO4 in 
acute asthma.4–10 The most recent review10 suggested that 
intravenous treatment seemed eﬀ ective in children but 
was unable to draw clear conclusions about treatment in 
adults. Both intravenous treatment (assessed in ten trials, 
with 955 adults) and nebulised treatment (seven trials, 
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430 adults) were associated with weak evidence of 
improved respiratory function compared with control 
populations all treated with standard care. No trials directly 
compared intravenous MgSO4 with nebulised MgSO4. The 
standardised mean diﬀ erence (SMD) in  respiratory 
function for intravenous treatment was 0·25 (95% CI 
–0·01 to 0·51; p=0·06) and for nebulised treatment 
was 0·17 (95% CI –0·02 to 0·36; p=0·09). Meta-analysis 
showed that intravenous treatment was associated with 
weak evidence of an eﬀ ect on hospital admission (relative 
risk [RR] 0·68, 95% CI 0·46 to 1·02; p=0·06), whereas 
nebulised treatment was associated with no signiﬁ cant 
eﬀ ect (0·87, 0·70 to 1·08; p=0·22) compared with standard 
care. One further trial of intravenous MgSO4 in adults11 has 
since been published. Inclusion of this trial in the meta-
analysis12 resulted in a slightly larger and signiﬁ cant eﬀ ect 
on respiratory function (SMD 0·35, 95% CI 0·06 to 0·64; 
p=0·02) but the eﬀ ect on hospital admission remained 
non-signiﬁ cant (RR 0·85, 95% CI 0·68 to 1·06; p=0·14). 
Whether changes in measures of respiratory function 
were associated with important changes in management 
of patients or a clinically meaningful improvement in 
symptoms was unclear.
Uncertainty in the evidence is shown in treatment 
recommendations. Current guidelines in the UK2 and 
the USA3 suggest that intravenous MgSO4 should be 
considered in adults with life-threatening features or 
severe acute asthma that has not responded to inhaled 
bronchodilator therapy. No recommendations are made 
regarding nebulised MgSO4.
We aimed to assess the eﬀ ectiveness of intravenous 
and nebulised MgSO4 in adults with severe acute asthma. 
We speciﬁ cally aimed to determine whether intravenous 
or nebulised MgSO4, used alongside standard treatment 
including salbutamol, reduces the proportion of patients 
requiring hospital admission at initial presentation or 
during the subsequent 7 days, and whether intravenous 
or nebulised MgSO4 improves patient-assessed levels of 
breathlessness up to 2 h after the start of treatment.
Methods
Study design and patients
We undertook a multicentre, double-blind, placebo-
controlled, three-arm, randomised trial at 34 emergency 
departments in the UK. The trial protocol was published 
previously.
Eligible patients were adults (aged ≥16 years) attending 
an emergency department with severe acute asthma 
(ie, acute asthma with either a peak expiratory ﬂ ow rate 
of <50% of best or predicted, respiratory rate >25 breaths 
per min, heart rate >110 beats per min, or inability to 
complete sentences in one breath). We excluded patients 
who had life-threatening features (oxygen saturation 
<92%, silent chest, cyanosis, poor respiratory eﬀ ort, 
bradycardia, arrhythmia, hypo tension, exhaustion, coma, 
or confusion), a contrain dication to either nebulised or 
intravenous MgSO4 (pregnancy, hepatic or renal failure, 
heart block, or known hypermagnesaemia), individuals 
who were unable to provide written or verbal consent, 
and previous participants in the 3Mg trial. We amended 
the protocol during the trial to also exclude individuals 
who had received MgSO4 in the 24 h before recruitment. 
We sought written or verbal consent from all participants. 
Patients who initially provided verbal consent were asked 
for written consent as soon as their condition permitted.
An independent data monitoring committee reviewed 
trial data at regular intervals and reported re com-
mendations to the trial steering committee in accordance 
with the data monitoring committee charter. The trial was 
approved by the Scotland A Research Ethics Committee. 
Randomisation and masking
We randomly allocated participants with a telephone or 
internet randomisation system, which was managed by 
339 randomly allocated 
         nebulised MgSO4
        333 received allocated 
                  intervention
              6 did not receive allocated 
                  intervention
             2 withdrew consent 
                     before treatment
                 4 treatment packs not 
           available
406 randomly allocated 
          intravenous MgSO4
        396 received allocated 
                   intervention
           10 did not receive 
                   intervention
                   7 withdrew consent 
                      before treatment
                   2 treatment packs not 
                       available
                   1 self-discharged before 
                       treatment
332 completed follow-up in 
         emergency department
152 completed questionnaire at 
         30 days
393 completed follow-up in 
         emergency department
186 completed questionnaire at 
          30 days
332 analysed
     7 excluded from analysis
         6 treatment not started
         1 ineligible patient (in prison)
394 analysed
    12 excluded from analysis
          10 treatment not started
             2 ineligible patients 
                 (previous participation)
2783 assessed for eligibility
1109 randomly allocated to treatment groups
1674 excluded
          847 ineligible*
                     466 life-threatening asthma
                         73 contraindicated
                         19 received magnesium in previous 24 h
                     319 previous participant
          200 declined to participate
          306 administrative reasons (emergency
                    department too busy, staﬀ not trained, 
                    or no treatment pack available)
             31 unable to provide consent
           201 other (eg, physician decision)
             89 reason not recorded
364 randomly allocated placebo
        358 received allocated 
                  intervention
             6 did not receive 
                   intervention
                  2 withdrew consent 
                      before treatment
                   3 treatment packs not 
                       available
                    1 self-discharged before 
                       treatment
357 completed follow-up in 
         emergency department
162 completed questionnaire at 
         30 days
358 analysed
     6 excluded from analysis
         6 treatment not started
Figure 1: Study proﬁ le
*Patients could meet ≥1 exclusion criteria. 
For the trial protocol see http://
www.thelancet.com/protocol-
reviews/08PRT-503
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the Sheﬃ  eld Clinical Trials Research Unit (CTRU). After 
entry into the trial, participants were allocated to 
numbered treatment packs kept in the emergency 
department. We used a simple randomisation sequence 
in the ﬁ rst 20 participating hospitals, but switched to 
blocked randomisation (block sizes of four or six), 
stratiﬁ ed by hospital, for subsequent hospitals to 
safeguard against new centres recruiting too few 
participants in any trial arm. Every treatment pack 
contained an intravenous infusion and three nebuliser 
solutions, either of which could be active treatment or 
placebo. Participants, hospital staﬀ , and research staﬀ  
were masked to allocated treatment.
Procedures
Patients were allocated to receive one of three treatments: 
intravenous MgSO4 (8 mmol [2 g] in 100 mL normal 
saline provided over 20 min) and three 7·5 mL vials of 
0·9% saline nebulised at 20 min intervals (intravenous 
MgSO4 group); intravenous normal saline (100 mL given 
over 20 min) and three 7·5 mL vials of 2 mmol (500 mg) 
MgSO4 nebulised at 20 min intervals (nebulised MgSO4 
group); or intravenous normal saline (100 mL given over 
20 min) and three 7·5 mL vials of 0·9% saline nebulised 
at 20 min intervals (placebo group). 
Patients received standard therapy in accordance with 
guidelines2 from the British Thoracic Society and Scottish 
Intercollegiate Guidelines Network and consisted of 
oxygen, nebulised salbutamol (5 mg), nebulised 
ipratropium (500 μg), and oral prednisolone administered 
during recruitment, followed by up to 5 mg salbutamol 
added to each trial nebuliser. Other treatments were 
provided at the discretion of the clinician. Patients were 
managed in the emergency department and data were 
collected until 2 h after randomisation. At this point, if 
not already undertaken, a ﬁ nal disposition decision was 
made (hospital admission or discharge) and initial data 
collection was completed.
We prespeciﬁ ed two primary outcomes. The ﬁ rst was a 
health service primary outcome, deﬁ ned as the 
proportion of patients admitted to hospital, either after 
emergency department treatment or at any time in the 
subsequent 7 days. The second was a patient-centred 
primary outcome, deﬁ ned as the patient’s visual analogue 
scale (VAS) for breathlessness in the 2 h after start of 
treatment. VAS breathlessness has been used to measure 
breathlessness during exercise13 and has been shown to 
correlate with respiratory function and symptomatic 
change in cohorts with acute asthma.14,15
Secondary outcomes included mortality, adverse 
events, use of ventilation or respiratory support, length of 
hospital stay, admission to a high-dependency unit or 
intensive-care unit, change in peak expiratory ﬂ ow rate 
and physiological variables (oxygen saturation, heart rate, 
respiratory rate, blood pressure) over 2 h, change in 
quality of life between baseline and 1 month, number of 
unscheduled health-care contacts over the subsequent 
month, and satisfaction with care (these outcomes will 
be reported elsewhere).
Treating clinicians routinely recorded adverse events 
and side-eﬀ ects occurring during emergency department 
treatment on case report forms. Key events (cardiac 
arrest, respiratory arrest, emergency intubation, non-
invasive ventilation, pneumothorax, and arrhythmia) 
Nebulised MgSO4 
(n=332)
Intravenous 
MgSO4 (n=394)
Placebo (n=358) Overall (n=1084)
Age, years
Mean 36·5 (14·8) 35·6 (13·1) 36·4 (14·1) 36·1 (14·0)
Median 35·0 (23·0–47·0) 34·0 (25·0–44·0) 34·5 (24·0–47·0) 34·0 (24·0–46·0)
Range 16–85 16–84 16–88 16–88
Sex, female 232 (70%) 279 (71%) 252 (70%) 763 (70%)
Ethnic group
White 286 (86%) 369 (94%) 319 (89%) 974 (90%)
Mixed 2 (1%) 1 (<1%) 5 (1%) 8 (1%)
Asian or Asian British 14 (4%) 8 (2%) 16 (4%) 38 (4%)
Black or black British 2 (1%) 5 (1%) 4 (1%) 11 (1%)
Other 2 (1%) 0 0 2 (<1%)
Not stated 22 (7%) 8 (2%) 11 (3%) 41 (4%)
Missing 4 (1%) 3 (1%) 3 (1%) 10 (1%)
Smoking status
Never 151 (45%) 156 (40%) 143 (40%) 450 (42%)
Current 98 (30%) 138 (35%) 127 (35%) 363 (33%)
Previous 72 (22%) 95 (24%) 81 (23%) 248 (23%)
Missing data 11 (3%) 5 (1%) 7 (2%) 23 (2%)
Predicted peak expiratory ﬂ ow rate, L per min
Data available 324 389 346 1059
Mean 430·0 (118·8) 431·8 (116·9) 435·0 (110·8) 432·3 (115·4)
Median 425·0 
(350·0–500·0)
435·0 
(350·0–500·0)
425·0 
(350·0–500·0)
425·0 
(350·0–500·0)
Range 100–700 140–800 150–790 100–800
Other previous serious 
lung disease
29 (9%) 42 (11%) 27 (8%) 98 (9%)
Other serious illness 69 (21%) 66 (17%) 68 (19%) 203 (19%)
Data are mean (SD), median (IQR), or n (%), unless otherwise stated.
Table 1: Baseline characteristics
Nebulised 
MgSO4 
(n=332)
Intravenous 
MgSO4 
(n=394)
Placebo 
(n=358)
Overall 
(n=1084)
Status at 4 h
Admitted 254 (77%) 279 (71%) 278 (78%) 811 (75%)
Discharged 77 (23%) 114 (29%) 80 (22%) 271 (25%)
Died 0 0 0 0
Unknown 1 (<1%) 1 (<1%) 0 2 (<1%)
Subsequent hospital admission within 7 days 15 (5%) 10 (3%) 7 (2%) 32 (3%)
Subsequent hospital admission after discharge 
at initial attendance
6 (2%) 5 (1%) 3 (1%) 14 (1%)
Admitted to hospital at any time within 7 days 261 (79%) 285 (72%) 281 (78%) 827 (76%)
Data are n (%).
Table 2: Admission to hospital 
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and common side-eﬀ ects (ﬂ ushing, nausea, vomiting, 
and hypotension [systolic pressure <100 mm Hg]) were 
speciﬁ cally sought and recorded. Other events were 
recorded on a general adverse event reporting form. 
A research nurse reviewed patient notes and recorded 
any side-eﬀ ects identiﬁ ed during treatment or adverse 
events occurring up to 30 days after treatment. We 
identiﬁ ed adverse events and reported them according to 
good clinical practice guidance.
Statistical analysis
We planned to recruit 1200 participants (400 patients per 
group). Assuming 80% of patients with severe acute 
asthma were admitted after emergency department 
management and hospital admission is recorded for all 
participants, the study would have 90% power to detect a 
10% absolute reduction in the proportion admitted (ie, to 
70%) for any pair of treatment groups compared (two-
sided α=0·05). Assuming 80% of participants had a VAS 
measurement, then the study would have 90% power to 
detect an 8 mm diﬀ erence in a 100 mm VAS at 2 h after 
treatment initiation (two-sided α=0·05). Previous data 
have established that the standard deviation on a 100 mm 
VAS is 30 mm, and that 22 mm represents a minimum 
clinically signiﬁ cant diﬀ erence.14 
We analysed participants in the groups to which they 
were allocated, irrespective of whether they actually 
received or completed the allocated treatment. We used 
logistic regression for analysis of admission rates. For 
length of stay, we compared means with censored normal 
regression and medians with log-normal regression to 
account for interval censoring in discharged patients (for 
whom no time of discharge was recorded) and also 
admissions that were ongoing at 30 days. We compared 
the number of days spent in the intensive-care unit or 
high-dependency unit with the Mann-Whitney U test. We 
used ANCOVA for assessment of all other outcomes. We 
assessed the primary outcome in all eligible patients who 
started treatment, adjusted for hospital of admission. We 
also did additional analyses with diﬀ erent imputation 
strategies as con ﬁ rmatory analyses. We did a secondary 
explanatory analysis restricted to individuals who 
completed the treatment as per protocol. We used Simes’s 
method,16 which is a modiﬁ cation of the Bonferroni 
method with increased power, to adjust for multiplicity 
arising from use of two primary outcomes. The two 
preplanned comparisons between the three groups were 
active treatment (intravenous or nebulised) versus 
placebo and intravenous MgSO4 versus nebulised MgSO4. 
We also present comparisons of intravenous MgSO4 
versus placebo and nebulised MgSO4 versus placebo for 
completeness. We undertook three preplanned subgroup 
analyses assessing the primary outcomes (hospital 
admission and VAS breathlessness) between active and 
placebo groups stratiﬁ ed by age (≥50 years vs <50 years), 
baseline peak expiratory ﬂ ow rate (less than median vs 
median or greater), and previous treatment with 
salbutamol before the trial treatments (yes vs no).
This study is registered, number ISRCTN04417063.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We recruited patients at 34 hospitals between July 30, 
2008, and June 30, 2012. Recruitment was slower than 
anticipated and ended when the trial funding expired 
after 1109 patients eligible for random allocation had 
been enrolled (ﬁ gure 1). Of these 1109 patients, 
25 withdrew without starting trial drug, were recruited in 
error (protocol violations), or could not be allocated to a 
treatment pack, leaving 1084 patients included in the 
analysis. Table 1 shows the baseline characteristics. Age 
and sex characteristics were balanced across the groups, 
but there were more white patients in the intravenous 
magnesium group and more patients who had never 
Nebulised MgSO4 
(n=332)
Intravenous MgSO4 
(n=394)
Placebo (n=358)
VAS at baseline
Patients assessed 326 (98%) 386 (98%) 349 (97%)
Mean, mm 61·6 (23·3) 61·9 (22·8) 63·1 (23·5)
Change in VAS at 1 h
Patients assessed 314 (95%) 372 (94%) 344 (96%)
Mean change, mm –18·4 (22·8) –24·2 (24·4) –21·5 (24·7)
Change in VAS at 2 h
Patients assessed 296 (89%) 357 (91%) 323 (90%)
Mean change, mm –28·2 (27·4) –34·3 (27·7) –31·3 (29·4)
Data are n (%) or mean (SD). VAS=visual analogue scale.
Table 3: Change in VAS breathlessness
Nebulised MgSO4 
(n=332)
Intravenous MgSO4 
(n=394)
Placebo (n=358)
Percentage predicted PEFR at baseline
Patients assessed 308 (93%) 375 (95%) 327 (91%)
Mean 50·0% (19·6) 54·3% (20·2) 50·5% (19·1)
Change in percentage PEFR at 1 h
Patients assessed 282 (85%) 349 (89%) 304 (85%)
Mean 9·9% (15·0) 11·4% (15·7) 10·2% (14·7)
Change in percentage PEFR at 2 h
Patients assessed 270 (81%) 337 (86%) 291 (81%)
Mean 13·4% (18·0) 14·4% (17·4) 14·4% (16·3)
Data are n (%) or mean (SD). PEFR=peak expiratory ﬂ ow rate.
Table 4: Change in percentage of predicted PEFR
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smoked in the nebulised magnesium group. The 
appendix shows the trial drugs received by the three 
groups of patients and concurrent treatments. The mean 
overall dose of nebulised solution was 21·3 mL (SD 3·9), 
with 917 (85%) of 1084 patients receiving the full dose of 
22·5 mL, and the mean total dose of intravenous infusion 
was 97·1 mL (SD 14·6) with 968 (89%) receiving the full 
intravenous infusion.
Table 2 and table 3 show the results of the primary 
outcome analysis. Rates of admission to hospital did not 
diﬀ er between groups for comparisons of active treatment 
and placebo (odds ratio 0·84, 95% CI 0·61–1·15; p=0·276), 
intravenous MgSO4 and nebulised MgSO4 (0·76, 
0·53–1·10; p=0·146), intravenous MgSO4 and placebo 
(0·73, 0·51–1·04; p=0·083), or nebulised MgSO4 and 
placebo (0·96, 0·65–1·40; p=0·819; table 2). Mean 
improvements in VAS (a positive value shows a greater 
improvement than in the comparator) did not diﬀ er 
between groups for comparisons of active treatment and 
placebo (0·0 mm, 95% CI –1·9 to 1·9; p=0·999), 
intravenous MgSO4 versus placebo (2·6 mm, –1·6 to 6·8; 
p=0·231), and nebulised MgSO4 versus placebo 
(–2·6 mm, –7·0 to 1·8; p=0·253), but the change in VAS 
was greater for patients in the intravenous MgSO4 group 
than it was in the nebulised MgSO4 group (5·1 mm, 
0·8 to 9·4; p=0·019; table 3). Further analyses were run 
with plausible imputations for the 108 (10%) patients with 
no 2 h change in VAS recorded; these analyses had no 
material eﬀ ect on the ﬁ ndings (data not shown).
Table 4 shows the analysis of peak expiratory ﬂ ow rate 
as a percentage of the predicted rate. The mean 
diﬀ erences in improvement in percentage predicted 
peak expiratory ﬂ ow rate at 2 h were –0·5% (95% CI 
–2·9 to 1·9; p=0·676) for active treatment versus placebo, 
0·3% (–2·4 to 3·0; p=0·841) for intravenous MgSO4 
versus nebulised MgSO4, –0·4% (–3·0 to 2·3; p=0·786) 
for intravenous MgSO4 versus placebo, and –0·6% 
(–3·4 to 2·1; p=0·652) for nebulised MgSO4 versus 
placebo (a positive value shows a greater improvement 
than in the comparator). Comparison of physiological 
measures identiﬁ ed no diﬀ erences between groups. Full 
details of physiological measures and oxygen ﬂ ow rates 
are provided in the appendix. 
Nebulised MgSO4 (n=332) Intravenous MgSO4 (n=394) Placebo (n=358) p values
Active vs placebo Intravenous vs 
nebulised MgSO4
Length of stay, h
Data available 329 (99%) 388 (98%) 353 (99%)
Mean 63·2 (79·7) 57·0 (75·1) 63·3 (84·3) 0·659 0·379
Median 35·1 (4·5–88·7) 31·5 (4·0–78·4) 36·4 (4·5–87·3) 0·432 0·230
Range 3–623 4–723 1–694
Days in an intensive-care unit
Patients with any stay 9 (3%) 11 (3%) 5 (1%) 0·161 0·947
Mean 3·3 (4·8) 3·1 (5·0) 2·9 (3·9)
Median 2·0 (1–4) 2·0 (0–4) 2·0 (0–4) 0·159 0·941
Days in a high-dependency unit
Patients with any stay 22 (7%) 23 (6%) 20 (6%) 0·690 0·661
Mean 3·3 (4·8) 3·1 (5·0) 2·9 (3·9)
Median 2·0 (1–4) 2·0 (0–4) 2·0 (0–4) 0·715 0·630
Required ventilation 3 (1%) 6 (2%) 4 (1%) 0·936 0·458
Non-invasive 2 (1%) 2 (1%) 3 (1%)
Emergency intubation 2 (1%) 4 (1%) 1 (<1%)
Data are n (%), mean (SD), or median (IQR), unless otherwise stated. 
Table 5: Length of stay, intensive-care unit and high-dependency unit admission, and use of ventilation
0
25
50
75
100
Pa
tie
nt
s i
n 
ho
sp
ita
l (
%
)
0 4 8 12 24 48 72 96
Time to discharge (h)
Placebo
Nebulised MgS04
Intravenous MgS04
Figure 2: Length of stay after initial hospital attendance
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Length of stay, rates of admission to the intensive-care 
unit or high-dependency unit, and use of respiratory 
support did not diﬀ er between groups (table 5). Figure 2 
shows the proportion of patients in hospital by treatment 
group as a function of time from hospital admission. 
Any small diﬀ erence between the groups had disappeared 
by 24 h.
Table 6 shows adverse events and side-eﬀ ects. 
Incidence of side-eﬀ ects was increased in patients who 
received active treatment compared with placebo (odds 
ratio 1·68, 95% CI 1·11–2·52; p=0·014) and the 
subgroups of intravenous MgSO4 compared with placebo 
(1·68, 1·07–2·63; p=0·025) and nebulised MgSO4 
compared with placebo 1·67 (1·05–2·66, p=0·031), but 
we noted no diﬀ erences between intravenous MgSO4 and 
nebulised MgSO4 (1·00, 0·66–1·52; p=0·988). Table 7 
shows the drugs prescribed to patients discharged after 
emergency department treatment. 218 (80%) of 
271 patients discharged at 4 h received prednisolone and 
100 (37%) received additional inhalers.
We noted no signiﬁ cant diﬀ erences on pre-planned 
subgroup analysis. Rates of hospital admission with 
intravenous MgSO4 did not diﬀ er from placebo (odds ratio 
0·76, 95% CI 0·45–1·30; p=0·332) in patients presenting 
with more severe asthma (deﬁ ned as median peak 
expiratory ﬂ ow rate or lower) or in individuals presenting 
with less severe asthma (0·67, 0·42–1·06; p=0·088). Data 
for rates of hospital admission split by age group and 
previous salbutamol treatment will be reported elsewhere.
Discussion
To our knowledge, the 3Mg trial is the largest trial of 
MgSO4 undertaken in acute asthma, the ﬁ rst trial 
powered to detect a meaningful diﬀ erence in rates of 
admission to hospital, and the ﬁ rst to directly compare 
intravenous treatment with nebulised treatment (panel). 
We did not show a clinically meaningful beneﬁ t from 
either intravenous or nebulised MgSO4 compared with 
placebo. Intravenous MgSO4 might have an eﬀ ect on 
rates of hospital admission and the conﬁ dence interval 
for this estimate included the possibility of both a 
worthwhile eﬀ ect and no eﬀ ect, but any eﬀ ect we noted 
on breathlessness was smaller than the minimum 
clinically signiﬁ cant diﬀ erence.13 We noted no suggestion 
of an eﬀ ect from nebulised MgSO4 in either primary 
outcome.
Meta-analysis of previous trials suggested evidence of 
beneﬁ t from intravenous and nebulised MgSO4.10 This 
suggestion contrasts with our ﬁ ndings of no beneﬁ t from 
nebulised treatment and weak evidence of beneﬁ t from 
intravenous treatment. Several factors might explain this 
inconsistency. Meta-analysis can be subject to publication 
bias if positive trials are preferentially submitted and 
accepted for publication. Some previous trials might 
have been restricted by inadequate allocation conceal-
ment or masking that inﬂ ated estimates of treatment 
eﬀ ects. Patients in all three arms of the 3Mg trial received 
treatment with nebulised β agonists which might have 
restricted the ability of MgSO4 to provide additional 
bronchodilation, whereas it was not always clear that all 
patients received optimum standard treatment in 
previous trials. Notably, patients in the control group of 
3Mg had improvements in peak expiratory ﬂ ow rate and 
VAS breathlessness, and few required respiratory 
support, suggesting a good response to standard 
treatment alone.
One potential explanation that can probably be 
discounted is that the 3Mg trial treatment was inadequate, 
in terms of the planned dose and actual amount of drug 
given. The protocol-speciﬁ ed doses of intravenous and 
nebulised MgSO4 were at the top end of doses used in 
previous trials, and most patients received the full dose 
Nebulised 
MgSO4 (n=332)
Intravenous 
MgSO4 (n=394)
Placebo 
(n=358)
Overall 
(n=1084)
Adverse events
Any adverse events 41 (12%) 53 (13%) 36 (10%) 130 (12%)
Arrhythmia 0 1 (<1%) 1 (<1%) 2 (<1%)
Cardiac arrest 0 1 (<1%) 0 1 (<1%)
Death 1 (<1%) 1 (<1%) 0 2 (<1%)
Intubation 2 (1%) 4 (1%) 1 (<1%) 7 (1%)
Non-invasive ventilation 2 (1%) 2 (1%) 3 (1%) 7 (1%)
Other (asthma related) 26 (8%) 26 (7%) 22 (6%) 74 (7%)
Other (non-asthma related) 14 (4%) 20 (5%) 12 (3%) 46 (4%)
Side-eﬀ ects
Any side-eﬀ ect 52 (16%) 61 (15%) 36 (10%) 149 (14%)
Flushing 3 (1%) 7 (2%) 2 (1%) 12 (1%)
Hypotension 31 (9%) 31 (8%) 22 (6%) 84 (8%)
Nausea 5 (2%) 14 (4%) 7 (2%) 26 (2%)
Vomiting 6 (2%) 6 (2%) 3 (1%) 15 (1%)
Other 12 (4%) 15 (4%) 5 (1%) 32 (3%)
Total number of events will not equal the sum of individual events if a patient has more than one side-eﬀ ect.
Table 6: Adverse events and side-eﬀ ects
Nebulised MgSO4 
(n=332)
Intravenous MgSO4 
(n=394)
Placebo 
(n=358)
Discharged at 4 h 77 (23%) 114 (29%) 80 (22%)
Any drug 64 (83%) 98 (86%) 64 (80%)
Prednisolone 62 (81%) 93 (82%) 63 (79%)
Salbutamol 21 (27%) 44 (39%) 27 (34%)
Fluticasone-salmeterol 3 (4%) 4 (4%) 2 (3%)
Beclometasone 1 (1%) 4 (4%) 3 (4%)
Budesonide 3 (4%) 3 (3%) 0
Ipratropium 1 (1%) 1 (1%) 0
Salmetarol 0 1 (1%) 0
Ipratropium-salbutamol 1 (1%) 0 0
Other 0 2 (2%) 0
Table 7: Drugs provided at discharge at 4 h
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of the relevant drugs (appendix). Pragmatic trials carry a 
risk that trial treatment will be delivered in a suboptimal 
manner, but we noted no evidence of this in the 3Mg 
trial.
Our ﬁ ndings for nebulised MgSO4 contrast with those 
of the MAGNETIC trial,17 which showed an improvement 
in asthma severity score at 60 min after treatment with 
nebulised MgSO4 compared with placebo in children and 
adolescents with acute severe asthma.17 Previous meta-
analysis10 suggested that intravenous MgSO4 is more 
eﬀ ective in children than adults. Findings from 3Mg and 
MAGNETIC suggest that the same is true of nebulised 
MgSO4.
The 3Mg trial had some limitations. The trial terminated 
when funding expired and had recruited 1109 patients 
(92%) of a target of 1200. Despite this shortfall, the trial 
had 84% power to detect a 10% diﬀ erence in admission 
rate for nebulised treatment versus placebo and 87% 
power for intravenous MgSO4 versus placebo based on 
the original sample-size projections. Furthermore, VAS 
breathlessness was recorded for 90% of the study 
population, as opposed to the anticipated 80% in the 
power calculation, so there was no loss of power to detect 
a diﬀ erence in this outcome.
3Mg was designed as a pragmatic trial to determine 
the eﬀ ectiveness of use of MgSO4 alongside other 
treatments as part of routine emergency department 
practice. The study population was pragmatically 
deﬁ ned by use of information routinely available to 
emergency department staﬀ . Thus, ﬁ ndings should be 
generalisable to typical adult patients attending hospital 
with acute asthma, but the design also means that the 
study population could have included some patients 
with other diagnoses. We assessed MgSO4 alongside 
standard treatment rather than comparing it to elements 
of standard treatment. This design might have reduced 
the potential for MgSO4 to make a clinically meaningful 
diﬀ erence, but withholding standard treatment would 
have been unethical. We selected primary outcomes that 
measured the eﬀ ect of treatment on symptoms (VAS 
breathlessness) and management (hospital admission). 
We also measured physiological parameters and peak 
expiratory ﬂ ow rate as secondary outcomes. Other 
measures, such as forced expiratory volume in 1 s, 
might have been more sensitive to changes in 
respiratory function, but these are not routinely 
measured in the emergency department, and would not 
provide evidence of clinical eﬀ ectiveness. Demonstration 
of clinical eﬀ ectiveness requires a meaningful 
improvement in symptoms or management of patients, 
not just a change in respiratory parameters. Finally, we 
deliberately excluded patients with life-threatening 
asthma and were unable to power the study to detect 
diﬀ erences in serious adverse outcomes (including 
death), so we were unable to determine whether MgSO4 
has an eﬀ ect on serious adverse outcomes in life-
threatening asthma.
The ﬁ ndings of our trial suggest that there is no role 
for nebulised MgSO4 in the management of severe acute 
asthma in adults and at best a limited role for intravenous 
MgSO4 in this setting. Patients receiving standard 
treatment had striking improvements in rates of 
breathlessness and peak expiratory ﬂ ow, and few required 
respiratory support. Although most patients were 
admitted to hospital, nebulised MgSO4 did not reduce the 
admission rate and we noted only weak evidence of an 
eﬀ ect from intravenous MgSO4. The low rate of side-
eﬀ ects and adverse events (other than those related to the 
underlying illness) suggests a low risk of harm from 
intravenous administration but the corresponding 
evidence of beneﬁ t is modest and uncertain.
Further clinical trials of MgSO4 in adults with acute 
asthma are unlikely to be worthwhile. If intravenous 
treatment has an eﬀ ect on admission rates or adverse 
events that was not detected by 3Mg then a much larger 
trial would be needed to detect such an eﬀ ect. The logistic 
barriers to undertaking clinical trials in patients with a 
medical emergency would seem to prevent a larger trial 
being feasible at an acceptable cost.
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Panel: Research in context
Systematic review
A 2007 systematic review,10 which was updated in 2009,12 
identiﬁ ed 11 trials of intravenous MgSO4 in 1018 adults and 
seven trials of nebulised MgSO4 in 430 adults with acute 
asthma. Meta-analysis suggested that both intravenous and 
nebulised treatment had potentially worthwhile eﬀ ects on 
respiratory function and showed non-signiﬁ cant trends 
towards reduced rates of admission to hospital.
Interpretation
Our large pragmatic study failed to provide convincing 
evidence that intravenous or nebulised MgSO4 produce 
clinically worthwhile beneﬁ ts in adults with severe acute 
asthma. Although MgSO4 is a safe treatment with few 
signiﬁ cant side-eﬀ ects, current data do not support a role 
for MgSO4 in the standard treatment of adults with severe 
acute asthma.
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Christopher Ellis, Amanda Loban, Kathryn MacKellar, 
Diana Papaioannou, and Martina Santarelli for their help with trial 
administration, monitoring and coordination, and data management.
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